Study To Evaluate The Efficacy And Safety Profile Of Two Investigational Medications For The Treatment of Alopecia Areata

Last Updated:
03/14/2017
Status:
Active/Fully Enrolled
Eligibility:
Age 18-75 with moderate to severe alopecia areata (with fixed hair loss for 7 years or less)
Drug:
JAK3 inhibitor and TYK2/JAK1 inhibitor
Administration:
Oral
Sponsor: 
Pfizer, Inc.

The purpose of this clinical research study is to evaluate the safety and effectiveness of two investigational medications, in tablet form, or placebo, for the treatment alopecia areata.